ANCHOR (OP-104) Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI): Phase 1 Update
Luděk Pour(University Hospital Brno), Enrique M. Ocio(Universidad de Salamanca), María‐Victoria Mateos(Hospital Clínico San Carlos), Vincent Ribrag(Institut Gustave Roussy), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Katell Le Dû(Clinique Victor Hugo), Paul G. Richardson(Harvard University), Lionel Karlin(Hôpital Lyon Sud), Albert Oriol(Institut Català d'Oncologia), Yvonne A. Efebera(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Miquel Granell(Hospital de Sant Pau), Vladimír Maisnar(Charles University), Roman Hájek(University Hospital Ostrava), Catriona Byrne(Oncopeptides (Sweden)), Jacques Delaunay(Hôtel-Dieu de Paris), Jean‐Richard Eveillard(Centre Hospitalier Régional Universitaire de Brest), Christian Jacques(Bibliothèque et Archives nationales du Québec), Malin Sydvander(University Hospital Brno), Jan Štraub(University Hospital Brno), Maxim Norkin(Centre Hospitalier Universitaire Vaudois)
Cited by 0
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k